It was first developed in 1991 as a derivative of Body Protection Compound, a peptide naturally found in human gastric juices [1, 2]
In another study, intraperitoneal administration of BPC-157 alleviated the effects of MPTP by improving somatosensory orientation, reducing hyperactivity and decreasing motor abnormalities
Key areas of active scientific investigation utilizing this combined research platform include: Gastric Acid Stability and Enhanced Bioavailability: Modeling the structural resilience of BPC-157 Arginate Salt
Anlisis de los mecanismos de accin del BPC-157 El potencial regenerativo del BPC-157 parece derivar de su capacidad para influir en mltiples vas biolgicas simultneamente
Despite its synthetic form, its designed to mimic the bodys own regenerative processes, especially in the areas of inflammation, tissue damage, and healing